1h Free Analyst Time
Theα4β7 Integrin Antagonists Market was valued at USD 244.15 million in 2024 and is projected to grow to USD 269.98 million in 2025, with a CAGR of 10.84%, reaching USD 452.81 million by 2030. Speak directly to the analyst to clarify any post sales queries you may have.
Unlocking the Potential of α4β7 Integrin Antagonists
The role of α4β7 integrin antagonists has grown exponentially as a cornerstone in the management of immune-mediated gastrointestinal disorders. These targeted biologic therapies, which include key agents that inhibit leukocyte trafficking to the gut mucosa, represent a paradigm shift away from broadly immunosuppressive regimens toward precision modulation of inflammatory pathways. As clinicians increasingly seek treatments that balance efficacy with safety, α4β7 integrin blockers have emerged as a preferred option for patients suffering from ulcerative colitis, Crohn’s disease, and related variants of inflammatory bowel disease.Against this backdrop, a rigorous exploration of the market dynamics, regulatory environment, and competitive landscape becomes essential for stakeholders in pharmaceuticals, biotechnology, and allied services. Drawing on extensive primary and secondary research, this executive summary distills the critical factors influencing development trajectories, commercialization strategies, and adoption rates of α4β7 integrin antagonists. Readers will gain a clear view of how these therapies are reshaping the standard of care, the challenges and opportunities they present, and the strategic imperatives required for sustained success in this rapidly evolving segment.
Rewriting the Therapeutic Playbook with α4β7 Inhibition
Recent advancements in biologic engineering and immunology have catalyzed transformative shifts in how α4β7 integrin antagonists are discovered, developed, and delivered. Enhanced screening platforms and structure-guided optimization techniques now enable developers to design molecules with higher selectivity for the β7 integrin subunit, minimizing off-target effects and elevating safety profiles. Concurrently, the growing emphasis on patient-centric care has prompted formulation innovations such as the development of subcutaneous administration options, expanding treatment settings beyond specialized infusion centers.Equally impactful are strategic partnerships between established pharmaceutical companies and nimble biotech ventures. These alliances facilitate the integration of novel drug delivery systems, real-world evidence platforms, and digital adherence tools into clinical development plans. Regulatory agencies worldwide have also responded by refining accelerated pathways for therapies targeting conditions with significant unmet need, thereby shortening time to patient access. Taken together, these developments underscore a new era in which technological prowess, collaborative frameworks, and regulatory agility converge to redefine the trajectory of α4β7 integrin antagonist therapy.
Navigating the New Tariff Regime Shaping Antagonist Accessibility
The imposition of additional tariffs on biologics and their raw materials in 2025 has introduced complexity into the supply chain and cost structures underpinning α4β7 integrin antagonist development and commercialization. Increased duties on imported mammalian cell culture reagents and advanced purification resins have elevated production expenses for both emerging biotech players and established contract manufacturing organizations. Consequently, companies are reevaluating sourcing strategies, exploring nearshoring of critical processes, and investing in localized manufacturing capabilities to mitigate exposure to volatile trade policies.Moreover, higher import costs are exerting pressure on pricing negotiations with payers and healthcare providers, particularly in regions where reimbursement frameworks are sensitive to incremental cost increases. In response, some developers are adopting tiered pricing models and value-based contracting to align payment with clinical outcomes. Simultaneously, collaborative consortia are forming to share best practices in supply chain resilience, fostering greater transparency and risk diversification. This multifaceted response to the new tariff regime underscores the importance of adaptive planning and cross-sector collaboration to sustain momentum in α4β7 integrin antagonist innovation.
Harnessing Market Segmentation to Drive Targeted Growth
A nuanced understanding of drug type segmentation reveals that mature agents alongside next-generation molecules each play a distinct role in the therapeutic arsenal. Natalizumab, a non-selective blocker, continues to demonstrate broad immunomodulatory effects that benefit patients with complex disease presentations, even as selective β7 integrin blockade emerges as a more targeted approach embodied by vedolizumab. This differentiation receives further refinement in administration mode segmentation, where intravenous delivery excels in controlled infusion settings and rapid onset of action, while subcutaneous formulations cater to patient convenience and long-term adherence outside clinical facilities.Mechanism of action segmentation highlights that non-selective integrin blockade remains indispensable for individuals requiring multi-pathway intervention, whereas selective β7 integrin antagonists offer tailored suppression of gut-homing lymphocytes, minimizing systemic immunosuppression. Meanwhile, therapeutic application segmentation underscores the varied clinical landscapes in which these agents operate. In ulcerative colitis, the focus on mucosal healing drives adoption of selective blockade, whereas Crohn’s disease management may benefit from the comprehensive scope provided by non-selective compounds. Broadly defined under the umbrella of inflammatory bowel disease, these options equip clinicians with a versatile toolkit to address diverse patient phenotypes and disease severities.
Regional Dynamics Defining α4β7 Integrin Antagonist Adoption
Regional dynamics shape the adoption curve and commercial trajectories of integrin antagonists in distinct ways across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, robust reimbursement frameworks, coupled with a well-established infusion center infrastructure, favor the deployment of intravenous therapies, even as payers demand evidence of long-term cost effectiveness. Transitioning from this mature environment, Europe, the Middle East & Africa exhibit a growing appetite for subcutaneous options, driven by initiatives aimed at lower hospital dependency and enhanced patient self-administration, although economic disparities within the region create varying levels of market access.Turning attention to Asia-Pacific, rapid expansion of healthcare infrastructure and increasing governmental focus on chronic disease management have created fertile ground for both intravenous and subcutaneous integrin antagonists. In this region, local manufacturers and global collaborators are co-developing biosimilar candidates to address price sensitivity and broaden access. Collectively, these regional distinctions underline the necessity of tailored go-to-market strategies that reflect reimbursement landscapes, patient preferences, and infrastructure capabilities in each geography.
Leading Innovators Driving α4β7 Integrin Antagonist Advancements
Innovation in the α4β7 integrin antagonist segment is driven by a blend of established pharmaceutical leaders and pioneering biotechs. Major market incumbents have leveraged their clinical development expertise and global commercial networks to bring flagship products to patients while investing in novel candidates aimed at enhancing safety and convenience profiles. At the forefront, companies with a track record in monoclonal antibody development are accelerating next-generation payloads that utilize advanced Fc engineering and multispecific constructs to broaden therapeutic impact.Concurrently, smaller biotechnology firms are carving out niches by focusing on precision immunology, integrating biomarker-driven patient selection, and exploring combination regimens that synergize with existing therapies. These agile innovators often enter collaborative agreements with contract research organizations and academic centers to expedite proof-of-concept studies and real-world evidence collection. Together, these diverse players foster a competitive ecosystem where strategic alliances, intellectual property portfolios, and differentiated clinical profiles determine leadership in the integrin antagonist domain.
Strategic Imperatives for Industry Leaders
Industry leaders must adopt a multi-pronged strategy that balances near-term commercialization goals with long-term research investments. Prioritizing flexible manufacturing platforms will enable faster scale-up and adaptability to shifting regulatory requirements, while integrating digital health tools can enhance patient engagement and real-world data capture. Early alignment with payers on value frameworks, supported by robust health economics and outcomes research, will smooth the path to reimbursement and solidify competitive positioning.From an R&D perspective, pursuing selective blockade approaches that target disease-specific integrin interactions offers an opportunity to differentiate pipelines and command premium pricing. Cultivating partnerships with academic institutions and technology providers can accelerate biomarker discovery, optimize trial designs, and reduce time to market. Finally, a commitment to sustainability in supply chain operations and transparent stakeholder communication will reinforce corporate reputation and foster trust among healthcare professionals and patients alike. By executing these strategic imperatives, companies can secure leadership in the dynamic α4β7 integrin antagonist market.
Robust Methodology Underpinning Comprehensive Market Analysis
The analysis presented here is grounded in a rigorous methodology that integrates multiple tiers of evidence and expert input. Extensive secondary research encompassed peer-reviewed literature, regulatory filings, clinical trial registries, and industry white papers. These sources provided a comprehensive view of the scientific, regulatory, and commercial factors shaping integrin antagonist development. To validate and enrich these insights, primary interviews were conducted with key opinion leaders, clinical investigators, payers, and executives within pharmaceutical and biotechnology organizations.Data triangulation techniques were employed to reconcile quantitative findings with qualitative perspectives, ensuring consistency and reducing potential bias. All information underwent a structured quality assurance process, including cross-verification with independent data repositories and stakeholder feedback loops. This robust approach ensures that the insights and recommendations offered reflect the latest market realities, scientific advancements, and strategic considerations necessary for informed decision-making in the α4β7 integrin antagonist landscape.
Charting the Path Forward in α4β7 Integrin Antagonist Development
In summary, α4β7 integrin antagonists have emerged as a transformative class of therapies that address critical needs in immune-mediated gastrointestinal conditions. Advances in molecular engineering, regulatory incentives, and innovative delivery formats have collectively expanded the therapeutic arsenal, offering patients safer and more convenient options. However, external factors such as the revised tariff landscape and regional reimbursement variability underscore the complexity of bringing these therapies to market at scale.Looking ahead, success will hinge on the ability to tailor development strategies to distinct patient populations, leverage segmentation insights, and forge strategic collaborations that accelerate clinical validation. Companies that embrace flexible manufacturing, champion value-based care models, and invest in data-driven decision-making will be best positioned to capture growth opportunities. As the field evolves, maintaining an unwavering focus on scientific excellence, operational resilience, and stakeholder alignment will be key to unlocking the full potential of α4β7 integrin antagonists.
Market Segmentation & Coverage
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:- Drug Type
- Natalizumab
- Vedolizumab
- Mode of Administration
- Intravenous
- Subcutaneous
- Mechanism of Action
- Non-Selective Integrin Blockade
- Selective β7 Integrin Blockade
- Therapeutic Application
- Crohn's Disease
- Inflammatory Bowel Disease
- Ulcerative Colitis
- Americas
- United States
- California
- Texas
- New York
- Florida
- Illinois
- Pennsylvania
- Ohio
- Canada
- Mexico
- Brazil
- Argentina
- United States
- Europe, Middle East & Africa
- United Kingdom
- Germany
- France
- Russia
- Italy
- Spain
- United Arab Emirates
- Saudi Arabia
- South Africa
- Denmark
- Netherlands
- Qatar
- Finland
- Sweden
- Nigeria
- Egypt
- Turkey
- Israel
- Norway
- Poland
- Switzerland
- Asia-Pacific
- China
- India
- Japan
- Australia
- South Korea
- Indonesia
- Thailand
- Philippines
- Malaysia
- Singapore
- Vietnam
- Taiwan
- Biogen
- C4X Discovery Ltd.
- EA Pharma Co., Ltd.
- Elli Lilly and Company
- Ensho Therapeutics, Inc.
- F. Hoffmann-La Roche AG
- Gilead Sciences, Inc.
- Merck
- Polypharma Group BV
- Protagonist Therapeutics Inc.
- Real-Gene Labs
- RedHill Biopharma Ltd.
- Takeda Pharmaceutical Company Limited
Table of Contents
1. Preface1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. α4β7 Integrin Antagonists Market, by Drug Type
8.1. Introduction
8.2. Natalizumab
8.3. Vedolizumab
9. α4β7 Integrin Antagonists Market, by Mode of Administration
9.1. Introduction
9.2. Intravenous
9.3. Subcutaneous
10. α4β7 Integrin Antagonists Market, by Mechanism of Action
10.1. Introduction
10.2. Non-Selective Integrin Blockade
10.3. Selective β7 Integrin Blockade
11. α4β7 Integrin Antagonists Market, by Therapeutic Application
11.1. Introduction
11.2. Crohn's Disease
11.3. Inflammatory Bowel Disease
11.4. Ulcerative Colitis
12. Americas α4β7 Integrin Antagonists Market
12.1. Introduction
12.2. United States
12.3. Canada
12.4. Mexico
12.5. Brazil
12.6. Argentina
13. Europe, Middle East & Africa α4β7 Integrin Antagonists Market
13.1. Introduction
13.2. United Kingdom
13.3. Germany
13.4. France
13.5. Russia
13.6. Italy
13.7. Spain
13.8. United Arab Emirates
13.9. Saudi Arabia
13.10. South Africa
13.11. Denmark
13.12. Netherlands
13.13. Qatar
13.14. Finland
13.15. Sweden
13.16. Nigeria
13.17. Egypt
13.18. Turkey
13.19. Israel
13.20. Norway
13.21. Poland
13.22. Switzerland
14. Asia-Pacific α4β7 Integrin Antagonists Market
14.1. Introduction
14.2. China
14.3. India
14.4. Japan
14.5. Australia
14.6. South Korea
14.7. Indonesia
14.8. Thailand
14.9. Philippines
14.10. Malaysia
14.11. Singapore
14.12. Vietnam
14.13. Taiwan
15. Competitive Landscape
15.1. Market Share Analysis, 2024
15.2. FPNV Positioning Matrix, 2024
15.3. Competitive Analysis
15.3.1. Biogen
15.3.2. C4X Discovery Ltd.
15.3.3. EA Pharma Co., Ltd.
15.3.4. Elli Lilly and Company
15.3.5. Ensho Therapeutics, Inc.
15.3.6. F. Hoffmann-La Roche AG
15.3.7. Gilead Sciences, Inc.
15.3.8. Merck
15.3.9. Polypharma Group BV
15.3.10. Protagonist Therapeutics Inc.
15.3.11. Real-Gene Labs
15.3.12. RedHill Biopharma Ltd.
15.3.13. Takeda Pharmaceutical Company Limited
16. ResearchAI
17. ResearchStatistics
18. ResearchContacts
19. ResearchArticles
20. Appendix
List of Figures
FIGURE 1. Α4Β7 INTEGRIN ANTAGONISTS MARKET MULTI-CURRENCY
FIGURE 2. Α4Β7 INTEGRIN ANTAGONISTS MARKET MULTI-LANGUAGE
FIGURE 3. Α4Β7 INTEGRIN ANTAGONISTS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY DRUG TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY DRUG TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MODE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MODE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024 VS 2030 (%)
FIGURE 14. GLOBAL Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. Α4Β7 INTEGRIN ANTAGONISTS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. Α4Β7 INTEGRIN ANTAGONISTS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. Α4Β7 INTEGRIN ANTAGONISTS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY NATALIZUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY VEDOLIZUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY NON-SELECTIVE INTEGRIN BLOCKADE, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY SELECTIVE Β7 INTEGRIN BLOCKADE, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY CROHN'S DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY ULCERATIVE COLITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. AMERICAS Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 20. AMERICAS Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 21. AMERICAS Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 22. AMERICAS Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 23. AMERICAS Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 24. UNITED STATES Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 25. UNITED STATES Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 26. UNITED STATES Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 27. UNITED STATES Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 28. UNITED STATES Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 29. CANADA Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 30. CANADA Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 31. CANADA Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 32. CANADA Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 33. MEXICO Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 34. MEXICO Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 35. MEXICO Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 36. MEXICO Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 37. BRAZIL Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 38. BRAZIL Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 39. BRAZIL Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 40. BRAZIL Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 41. ARGENTINA Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 42. ARGENTINA Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 43. ARGENTINA Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 44. ARGENTINA Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 45. EUROPE, MIDDLE EAST & AFRICA Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 46. EUROPE, MIDDLE EAST & AFRICA Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 47. EUROPE, MIDDLE EAST & AFRICA Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 48. EUROPE, MIDDLE EAST & AFRICA Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 49. EUROPE, MIDDLE EAST & AFRICA Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 50. UNITED KINGDOM Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 51. UNITED KINGDOM Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 52. UNITED KINGDOM Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 53. UNITED KINGDOM Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 54. GERMANY Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 55. GERMANY Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 56. GERMANY Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 57. GERMANY Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 58. FRANCE Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 59. FRANCE Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 60. FRANCE Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 61. FRANCE Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 62. RUSSIA Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 63. RUSSIA Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 64. RUSSIA Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 65. RUSSIA Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 66. ITALY Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 67. ITALY Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 68. ITALY Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 69. ITALY Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 70. SPAIN Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 71. SPAIN Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 72. SPAIN Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 73. SPAIN Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 74. UNITED ARAB EMIRATES Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 75. UNITED ARAB EMIRATES Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 76. UNITED ARAB EMIRATES Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 77. UNITED ARAB EMIRATES Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 78. SAUDI ARABIA Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 79. SAUDI ARABIA Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 80. SAUDI ARABIA Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 81. SAUDI ARABIA Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 82. SOUTH AFRICA Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 83. SOUTH AFRICA Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 84. SOUTH AFRICA Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 85. SOUTH AFRICA Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 86. DENMARK Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 87. DENMARK Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 88. DENMARK Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 89. DENMARK Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 90. NETHERLANDS Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 91. NETHERLANDS Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 92. NETHERLANDS Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 93. NETHERLANDS Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 94. QATAR Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 95. QATAR Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 96. QATAR Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 97. QATAR Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 98. FINLAND Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 99. FINLAND Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 100. FINLAND Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 101. FINLAND Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 102. SWEDEN Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 103. SWEDEN Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 104. SWEDEN Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 105. SWEDEN Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 106. NIGERIA Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 107. NIGERIA Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 108. NIGERIA Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 109. NIGERIA Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 110. EGYPT Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 111. EGYPT Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 112. EGYPT Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 113. EGYPT Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 114. TURKEY Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 115. TURKEY Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 116. TURKEY Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 117. TURKEY Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 118. ISRAEL Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 119. ISRAEL Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 120. ISRAEL Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 121. ISRAEL Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 122. NORWAY Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 123. NORWAY Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 124. NORWAY Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 125. NORWAY Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 126. POLAND Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 127. POLAND Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 128. POLAND Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 129. POLAND Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 130. SWITZERLAND Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 131. SWITZERLAND Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 132. SWITZERLAND Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 133. SWITZERLAND Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 134. ASIA-PACIFIC Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 135. ASIA-PACIFIC Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 136. ASIA-PACIFIC Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 137. ASIA-PACIFIC Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 138. ASIA-PACIFIC Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 139. CHINA Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 140. CHINA Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 141. CHINA Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 142. CHINA Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 143. INDIA Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 144. INDIA Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 145. INDIA Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 146. INDIA Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 147. JAPAN Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 148. JAPAN Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 149. JAPAN Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 150. JAPAN Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 151. AUSTRALIA Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 152. AUSTRALIA Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 153. AUSTRALIA Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 154. AUSTRALIA Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 155. SOUTH KOREA Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 156. SOUTH KOREA Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 157. SOUTH KOREA Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 158. SOUTH KOREA Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 159. INDONESIA Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 160. INDONESIA Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 161. INDONESIA Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 162. INDONESIA Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 163. THAILAND Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 164. THAILAND Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 165. THAILAND Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 166. THAILAND Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 167. PHILIPPINES Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 168. PHILIPPINES Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 169. PHILIPPINES Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 170. PHILIPPINES Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 171. MALAYSIA Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 172. MALAYSIA Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 173. MALAYSIA Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 174. MALAYSIA Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 175. SINGAPORE Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 176. SINGAPORE Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 177. SINGAPORE Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 178. SINGAPORE Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 179. VIETNAM Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 180. VIETNAM Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 181. VIETNAM Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 182. VIETNAM Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 183. TAIWAN Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 184. TAIWAN Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 185. TAIWAN Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 186. TAIWAN Α4Β7 INTEGRIN ANTAGONISTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 187. Α4Β7 INTEGRIN ANTAGONISTS MARKET SHARE, BY KEY PLAYER, 2024
TABLE 188. Α4Β7 INTEGRIN ANTAGONISTS MARKET, FPNV POSITIONING MATRIX, 2024
Companies Mentioned
The companies profiled in this α4β7 Integrin Antagonists market report include:- Biogen
- C4X Discovery Ltd.
- EA Pharma Co., Ltd.
- Elli Lilly and Company
- Ensho Therapeutics, Inc.
- F. Hoffmann-La Roche AG
- Gilead Sciences, Inc.
- Merck
- Polypharma Group BV
- Protagonist Therapeutics Inc.
- Real-Gene Labs
- RedHill Biopharma Ltd.
- Takeda Pharmaceutical Company Limited
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 198 |
| Published | May 2025 |
| Forecast Period | 2025 - 2030 |
| Estimated Market Value ( USD | $ 269.98 Million |
| Forecasted Market Value ( USD | $ 452.81 Million |
| Compound Annual Growth Rate | 10.8% |
| Regions Covered | Global |
| No. of Companies Mentioned | 14 |
